Ependymoma gene expression profiles associated with histological subtype, proliferation, and patient survival

Ependymomas are primary tumors of the central nervous system that typically originate from the walls of the cerebral ventricles or from the spinal canal. The pathogenesis of these tumors is poorly understood, and prognostic assessment based on histologic features and clinical parameters is difficult. The aim of this study was to investigate the molecular heterogeneity of ependymomas. We used cDNA microarrays and RT-PCR to examine gene expression in 47 ependymomas. We present results for five comparisons: (1) tumors from children and adults with poor versus favorable outcome, (2) tumors from children with poor versus favorable outcome, (3) tumors with high versus low proliferation indices, (4) subependymomas versus myxopapillary ependymomas, and (5) spinal versus intracranial ependymomas. For patients with an overall survival >10 years after diagnosis, we identified 27 genes associated with favorable prognosis. In contrast, overexpression of BNIP3, MRC1, EPHB3, GLIS3, CDK4, COL4A2, EBP, NRCAM, and CCNA1 genes in tumors with high proliferation indices was associated with a poor outcome. Thirty genes, including ETV6, YWHAE, TOP2A, TLR2, IRAK1, TIA1, and UFD1L were found to be highly expressed in subependymomas but not myxopapillary ependymomas. Also, 30 genes were differentially expressed in spinal versus intracranial ependymomas. There was no relationship between expression profiles and tumor grade, patient age, and patient gender. Our results provide insight into specific molecular events underlying ependymoma tumorigenesis and may contribute to more accurate diagnosis and prediction of clinical outcome.

[1]  J. Davis.  Bioinformatics and Computational Biology Solutions Using R and Bioconductor , 2007 .

[2]  D. Brat,et al.  Chromosomal abnormalities subdivide ependymal tumors into clinically relevant groups. , 2001, The American journal of pathology.

[3]  S. Leenstra,et al.  Proliferation- and Apoptosis-related Proteins in Intracranial Ependymomas: An Immunohistochemical Analysis , 2004, Journal of Neuro-Oncology.

[4]  A. Korshunov,et al.  The histologic grade is a main prognostic factor for patients with intracranial ependymomas treated in the microneurosurgical era , 2004, Cancer.

[5]  Joakim Lundeberg,et al.  Expression profiling of adrenocortical neoplasms suggests a molecular signature of malignancy. , 2005, Surgery.

[6]  R. Alterman,et al.  Colony stimulating factor-1 expression in human glioma , 1994, Molecular and chemical neuropathology.

[7]  Blanca Suarez-Merino,et al.  Microarray analysis of pediatric ependymoma identifies a cluster of 112 candidate genes including four transcripts at 22q12.1-q13.3. , 2005, Neuro-oncology.

[8]  K. Dieckmann,et al.  Role of radiotherapy in anaplastic ependymoma in children under age of 3 years: results of the prospective German brain tumor trials HIT-SKK 87 and 92. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[9]  D. Figarella-Branger,et al.  Prognostic factors in intracranial ependymomas in children. , 2000, Journal of neurosurgery.

[10]  M. Alonso,et al.  Analysis of the NF2 gene in oligodendrogliomas and ependymomas. , 2002, Cancer genetics and cytogenetics.

[11]  Shin Jung,et al.  Cell surface aggregation of elastin receptor molecules caused by suramin amplified signals leading to proliferation of human glioma cells , 1999, Acta Neuropathologica.

[12]  S. Vermeulen,et al.  Cell adhesion molecule Nr‐CAM is over‐expressed in human brain tumors , 1998, International journal of cancer.

[13]  Amar Gajjar,et al.  Radial glia cells are candidate stem cells of ependymoma. , 2005, Cancer cell.

[14]  J. Tonn,et al.  Loss of heterozygosity on chromosome 22 in human ependymomas , 2002, Acta Neuropathologica.

[15]  Patrik Edén,et al.  Molecular signatures in childhood acute leukemia and their correlations to expression patterns in normal hematopoietic subpopulations. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[16]  A. Look,et al.  Chromosome arm 6q loss is the most common recurrent autosomal alteration detected in primary pediatric ependymoma , 1999, Genes, chromosomes & cancer.

[17]  J. Dumanski,et al.  Localization of a putative low‐penetrance ependymoma susceptibility locus to 22q11 using a chromosome 22 tiling‐path genomic microarray , 2005, Genes, chromosomes & cancer.

[18]  D. Schiffer,et al.  Prognosis of ependymoma , 1998, Child's Nervous System.

[19]  V. Collins.  Gene amplification in human gliomas , 1995, Glia.

[20]  D. Gutmann,et al.  Alterations of protein 4.1 family members in ependymomas: a study of 84 cases , 2005, Modern Pathology.

[21]  S. Elledge,et al.  Human Claspin works with BRCA1 to both positively and negatively regulate cell proliferation. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[22]  H. Konishi,et al.  Identification of frequent G(2) checkpoint impairment and a homozygous deletion of 14-3-3epsilon at 17p13.3 in small cell lung cancers. , 2002, Cancer research.

[23]  D. Raidoo,et al.  Localization of the endothelin system in human diffuse astrocytomas , 2005, Cancer.

[24]  D. Ellison,et al.  Genomic imbalances in pediatric intracranial ependymomas define clinically relevant groups. , 2002, The American journal of pathology.

[25]  S. Mandel,et al.  Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes , 2004, Journal of Neural Transmission.

[26]  W. Mandemakers,et al.  An Oligodendrocyte Lineage-Specific Semaphorin, Sema5A, Inhibits Axon Growth by Retinal Ganglion Cells , 2004, The Journal of Neuroscience.

[27]  H. Budka,et al.  Ki-67 Immunolabeling Index Is an Accurate Predictor of Outcome in Patients With Intracranial Ependymoma , 2004, The American journal of surgical pathology.

[28]  P. Lichter,et al.  Gene expression patterns in ependymomas correlate with tumor location, grade, and patient age. , 2003, The American journal of pathology.

[29]  C. Meisner,et al.  Combined postoperative irradiation and chemotherapy for anaplastic ependymomas in childhood: results of the German prospective trials HIT 88/89 and HIT 91. , 2000, International journal of radiation oncology, biology, physics.

[30]  H. Mehdorn,et al.  Expression of VEGF and its receptors in different brain tumors , 2005, Neurological research.

[31]  G. Murphy,et al.  Antisense human neuroglia related cell adhesion molecule hNr-CAM, reduces the tumorigenic properties of human glioblastoma cells. , 1999, Anticancer research.

[32]  P. Starostik,et al.  Human ependymomas reveal frequent deletions on chromosomes 6 and 9 , 2003, Acta Neuropathologica.

[33]  Martin Vingron,et al.  Variance stabilization applied to microarray data calibration and to the quantification of differential expression , 2002, ISMB.

[34]  Rafael A. Irizarry,et al.  Bioinformatics and Computational Biology Solutions using R and Bioconductor , 2005 .

[35]  David E. Misek,et al.  Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction. , 2003, The American journal of pathology.

[36]  Gordon K. Smyth,et al.  limma: Linear Models for Microarray Data , 2005 .

[37]  E. Rushing,et al.  Supratentorial extraventricular ependymal neoplasms , 2005, Cancer.

[38]  R. Tibshirani,et al.  Diagnosis of multiple cancer types by shrunken centroids of gene expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[39]  H. Axer,et al.  Characterization of human glucose transporter (GLUT) 11 (encoded by SLC2A11), a novel sugar-transport facilitator specifically expressed in heart and skeletal muscle. , 2001, The Biochemical journal.

[40]  M. J. van den Bent,et al.  Identification of relevant prognostic histopathologic features in 69 intracranial ependymomas, excluding myxopapillary ependymomas and subependymomas , 2006, Cancer.

[41]  C. Tseng,et al.  Multivariate Analysis of Clinical Prognostic Factors in Children with Intracranial Ependymomas , 2004, Journal of Neuro-Oncology.

[42]  I. Germano,et al.  Arsenic trioxide induces autophagic cell death in malignant glioma cells by upregulation of mitochondrial cell death protein BNIP3 , 2005, Oncogene.

[43]  C. Rickert.  Prognosis‐Related Molecular Markers in Pediatric Central Nervous System Tumors , 2004, Journal of neuropathology and experimental neurology.

[44]  Jingde Zhu,et al.  Methylation profiles of thirty four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma , 2004, BMC Cancer.

[45]  A. Brandes,et al.  A multicenter study of the prognosis and treatment of adult brain ependymal tumors , 2004, Cancer.

[46]  T. Speed,et al.  Statistical issues in cDNA microarray data analysis. , 2003, Methods in molecular biology.

[47]  G. Reifenberger,et al.  Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas. , 1999, The American journal of pathology.

[48]  T. Wong,et al.  A clinicopathologic study of 81 patients with ependymomas and proposal of diagnostic criteria for anaplastic ependymoma , 2004, Journal of Neuro-Oncology.

[49]  P. Sorensen,et al.  ETV6-NTRK3: a chimeric protein tyrosine kinase with transformation activity in multiple cell lineages. , 2005, Seminars in cancer biology.

[50]  D. Sretavan,et al.  Invariant Sema5A inhibition serves an ensheathing function during optic nerve development , 2003, Development.

[51]  R. Allibone,et al.  Genetic abnormalities detected in ependymomas by comparative genomic hybridisation , 2002, British Journal of Cancer.